Nachrichten zur Abbvie Inc. Aktie

Can ABBVs Neuroscience Drugs Drive Growth in the Second Half of 2026?

AbbVies neuroscience franchise posts strong first-half growth, with Vyalev accelerating and tavapadon poised to add another potential growth driver.…

ATOS: Multiple Catalysts Converge in 2H26

By David Bautz, PhDNASDAQ: ATOSREAD THE FULL ATOS RESEARCH REPORTBusiness UpdateAtossa Therapeutics, Inc. (NASDAQ: ATOS) is approaching a potentially important…

How Much Did Immunology Drugs Contribute to AbbVies Q2 Performance?

Skyrizi and Rinvoq drive ABBVs Q2 growth, with strong sales, market-share gains and new indications supporting the immunology franchise.…

Is It Worth Investing in AbbVie (ABBV) Based on Wall Streets Bullish Views?

According to the average brokerage recommendation (ABR), one should invest in AbbVie (ABBV). It is debatable whether this highly sought-after…

AbbVie Sees Strong Demand for Its $10 Billion M&A Bond Sale

Investors flocked to drugmaker AbbVie Inc.’s $10 billion investment-grade bond sale after signs of investor fatigue for new debt to…

Teuer erkauftes Wachstum! AbbVie korrigiert seine Jahresprognose nach Milliarden-Deal für Apogee!

Umsatz & Gewinn über Erwartung: AbbVie liegt mit einem Gesamtumsatz von 17,0 Mrd. USD und einem EPS von 3,65…

AbbVie Inc. (ABBV) Q2 2026 Earnings Call Transcript

…

ABBV Beats on Q2 Earnings & Sales, Cuts 26 EPS View, Stock Down

AbbVie tops Q2 earnings and revenue estimates on strong immunology drug sales, but a lower 2026 EPS outlook tied to…

Goldman Sachs uncovers key AbbVie stock signals before earnings

AbbVie(ABBV) reports second-quarter results on Friday, July 31, and the mood around the stock has changed. A few months ago,…

Can These 5 Biotech Stocks Beat Wall Streets Q2 Estimates?

Biotech earnings take center stage as Viking, Biogen, Bristol Myers, Regeneron and AbbVie prepare to report Q2 2026 results.…

Should You Buy, Hold or Sell ABBV Stock Ahead of Q2 Earnings?

AbbVie heads into Q2 earnings with Skyrizi and Rinvoq driving growth as investors weigh Humira declines and the companys long-term…

Why Wall Street Cant Get Enough of This Dividend King

AbbVie has an attractive 2.7% yield, a solid pharmaceutical business, and is clearly focused on its dividend.…

AbbVie: A Dividend Fortress At An Appealing Price Tag

…

AbbVie (ABBV) Beats Stock Market Upswing: What Investors Need to Know

AbbVie (ABBV) closed at $256.18 in the latest trading session, marking a +1.11% move from the prior day.…

Abbvie: Wie zielt eine neue Ästhetik-Strategie auf zögerliche Patienten ab?

Die Europäische Kommission hat am 17. Juli 2026 das Neurotoxin Boey (trenibotulinumtoxinE) von Abbvies Tochtergesellschaft Allergan Aesthetics zugelassen. Mit…

3 Rock-Solid Dividend Stocks to Buy and Hold for Decades

AbbVie, Enbridge, and Coca-Cola pay high dividends and are the types of stocks that investors can buy and forget about.…

AbbVie Is Already a Dividend King. Heres Why the $10.9 Billion Apogee Deal Could Make It a Dynasty

AbbVie inherited its status as a Dividend King, but it is building a strong foundation to continue the dividend streak.…

AbbVie: Apogee-Deal und Krebs-Erfolg befeuern die Aktie

Phase-3-Daten zu Epcoritamab zeigen eine beeindruckende Reduktion des Krankheitsfortschritts in der Krebsmedizin um bis zu 60 %. Die strategische…

AbbVie Aktie: Kursziel rauf, Kaufempfehlung bestätigt

New York (www.aktiencheck.de) - AbbVie-Aktienanalyse von Cantor Fitzgerald:Cantor Fitzgerald habe das Kursziel für die Aktie von AbbVie Inc. (ISIN: US00287Y1091,…

Expanding RINVOQ And SKYRIZI Uses Might Change The Case For Investing In AbbVie (ABBV)

In late June 2026, AbbVie reported multiple product wins, including new pediatric approvals for SKYRIZI, positive CHMP opinions for RINVOQ…

House committee investigates Merck, AbbVie over China trials

Five of the biggest names in American pharma just got a deadline from Washington. The House Select Committee on China…

J&J or AbbVie: Which Stock Deserves a Place in Your Portfolio Now?

JNJ and ABBV both offer solid long-term growth potential, but differences in diversification, pipeline strength and estimates may give one…

This Pharmaceutical Giant Just Poured $11 Billion on an Acquisition. Time to Buy?

AbbVie knows how to plan ahead.…

What Sparked the $43B Jump in AbbVies Market Cap in the Past Week?

ABBV surged nearly 11% in a week as acquisitions, new approvals and pipeline expansion strengthen confidence in its long-term growth…

Exclusive-US House committee opens investigation into Merck, AbbVie China drug trials

Exclusive-US House committee opens investigation into Merck, AbbVie China drug trials…

AbbVie (ABBV) Moves 4.2% Higher: Will This Strength Last?

AbbVie (ABBV) saw its shares surge in the last session with trading volume being higher than average. The latest trend…

AbbVie gets positive EU opinion for vitiligo treatment

AbbVie gets positive EU opinion for vitiligo treatment…

Moderna, Eli Lilly & Co. auf Rekordkurs: Warum Anleger zunehmend auf Healthcare-Aktien setzen

Eli Lilly, AbbVie und Moderna erreichen vor dem Wochenende neue Höchststände Moderna stärkster Tagesgewinn im S&P 500: Moderne mRNA-Strategie…

AbbVie vs. Pfizer: Which Pharma Giant Stock Is a Better Buy in 2026?

AbbVie and Pfizer are taking divergent paths to navigate patent expirations and competition. Dig into their financials, risk profiles, and…

AbbVie Aktie springt 6%: Milliarden-Übernahme soll Skyrizi absichern

Bad Marienberg (www.aktiencheck.de) - Die AbbVie-Aktie hat Anlegern einen bemerkenswerten Handelstag beschert. Mit einem Kurssprung von 6,25% auf 230,01 USD…

Stock Market Today, June 22: Apogee Therapeutics Soars on AbbVie Cash Buyout Offer

On June 22, 2026, Apogee Therapeutics shares surged as investors reacted to AbbVies proposed acquisition terms.…

AbbVie Inc. (ABBV) M&A Call Transcript

…

SpaceX’s Big AI Bond Bet | Open Interest 6/22/2026

Get a jump start on the US trading day with Matt Miller and Dani Burger on "Bloomberg Open Interest." Stocks…

Truist reiterates Kymera stock Buy rating after AbbVie deal

Truist reiterates Kymera stock Buy rating after AbbVie deal…

The Clubs top 10 things to watch in the stock market Monday

Abbvie makes a move in M&A, and SpaceX is started with a hold rating at KeyBanc.…

AbbVie to acquire Apogee Therapeutics in $10.9B deal

Abbvie Inc (NYSE:ABBV) announced that it will acquire Apogee Therapeutics (NASDAQ:APGE) in an all-cash transaction valued at approximately $10.9 billion,...…

AbbVie vor Milliarden-Zukauf von Apogee Therapeutics! Die Post-Humira-Ära nimmt Formen an!

AbbVie steht kurz vor einer 10,9 Mrd. USD schweren Übernahme von Apogee Therapeutics, um das Kernsegment Immunologie abzusichern Durch…

AbbVie and Merck Face-Off: Which Pharma Stock Has the Lead?

ABBVs successful transition beyond Humira and growth from newer medicines give it an edge over MRK in this oncology-immunology showdown.…

AbbVies biggest deal since 2019 could land soon

AbbVie (ABBV) is closing in on a deal to buy Apogee Therapeutics for $10.9 billion in cash, according to a…

Medincell shares dive 15% as FY26 loss widens, AbbVie trial delayed

Medincell shares dive 15% as FY26 loss widens, AbbVie trial delayed…

Brokers Suggest Investing in AbbVie (ABBV): Read This Before Placing a Bet

Based on the average brokerage recommendation (ABR), AbbVie (ABBV) should be added to ones portfolio. Wall Street analysts overly optimistic…

AbbVie (ABBV) Rises Higher Than Market: Key Facts

AbbVie (ABBV) closed at $227.73 in the latest trading session, marking a +1.32% move from the prior day.…

AbbVie (ABBV) Ascends While Market Falls: Some Facts to Note

AbbVie (ABBV) closed at $227.23 in the latest trading session, marking a +1.02% move from the prior day.…

AbbVie Gets EU Nod for Aquipta as Acute Treatment for Migraine

ABBV wins EU approval for Aquipta for acute migraine treatment in adults, adding a second approved indication in migraine.…

Johnson & Johnson Hopes to Dethrone AbbVies Biggest Growth Driver. Heres Why Investors Shouldnt Panic

AbbVies shareholders can sleep easy.…

CytomX (CTMX) Q4 2025 Earnings Transcript

Image source: The Motley Fool.DATEMonday, Mar. 16, 2026 at 8 a.m. ETCALL PARTICIPANTSChief Executive Officer and Chairman — Sean McCarthy,…

The S&P 500 Is Expensive, but These 3 Dividend Stocks Still Look Like Bargains

AbbVie, CVS Health, and Verizon Communications are all high-yielding stocks with attractive valuations and robust financials.…

CEO Chat with Steven Quay, MD, PhD, Chairman, President, & CEO of Atossa Therapeutics

NASDAQ: ATOSDavid Bautz, PhD: Welcome to the next episode of our CEO Chat series. My name is David Bautz, and…

AbbVie Inc. (ABBV) Presents at EU Clinical Trial Regulation: Latest Developments and Upcoming Opportunities Transcript

…

AbbVie (ABBV) Up 3.5% Since Last Earnings Report: Can It Continue?

AbbVie (ABBV) reported earnings 30 days ago. Whats next for the stock? We take a look at earnings estimates for…